search
Back to results

A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke

Primary Purpose

Stroke, Ischemic

Status
Unknown status
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Induction of neural stem cells
Sponsored by
Allife Medical Science and Technology Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke, Ischemic

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study procedures.
  2. Men and women 30-65 years old.
  3. Women must have a negative serum pregnancy test, gestation age women practice an acceptable method of contraception.
  4. At least 12 months but no more than 60 months from time of hemorrhagic stroke, with a motor neurological deficit.
  5. Documented history of single hemorrhagic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement, with correlated findings by MRI.
  6. Modified Rankin Score of 2, 3 or 4.
  7. FMMS score of 55 or less, two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 5 point change in the FMMS.
  8. Two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 4 point change in the NIHSS.
  9. Able and willing to undergo post-physical therapy/rehabilitation.

Exclusion Criteria:

  1. Any disabling psychological or psychiatric disorders which may confound the study.
  2. History of more than one hemorrhagic stroke.
  3. History of another major neurological disease or injury.
  4. Cerebral soften lesion size >5cm in any one measurement.
  5. Myocardial infarction within the prior 3 months.
  6. History of seizures or current use of antiepileptic medication.
  7. History of peripheral nerve surgery, including Selective Dorsal Rhizotomy and Contralateral Seventh Cervical Nerve Transfer.
  8. Receipt of any investigational drug or device within 30 days.
  9. Receipt of any cell infusion other than blood transfusion.
  10. Any concomitant medical disease or condition noted below:

    1. Coagulopathy.
    2. Active or history of malignancy.
    3. Primary or secondary immune deficiency.
    4. Persistent MRI artifact or unable to undergo MRI.
  11. Any condition that the Investigator or primary physician feels may interfere with participation in the study or may endanger the subject.
  12. Any condition that the surgeon feels may pose complications for the surgery.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    iNSC treatment group

    Arm Description

    Outcomes

    Primary Outcome Measures

    Incidence of Treatment Emergent AE

    Secondary Outcome Measures

    Full Information

    First Posted
    October 29, 2018
    Last Updated
    October 29, 2018
    Sponsor
    Allife Medical Science and Technology Co., Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03725865
    Brief Title
    A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke
    Official Title
    A Clinical Study of Intracerebral Transplantation of Human Peripheral Blood Derived Induced Neural Stem Cells for Cerebral Hemorrhagic Stroke
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2018
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 2019 (Anticipated)
    Primary Completion Date
    March 2019 (Anticipated)
    Study Completion Date
    March 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Allife Medical Science and Technology Co., Ltd.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This is a single centre、single arm、open-label,to investigate the safety and efficacy of induction of neural stem cells transplantation in the brain

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Stroke, Ischemic

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Early Phase 1
    Interventional Study Model
    Sequential Assignment
    Masking
    None (Open Label)
    Enrollment
    12 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    iNSC treatment group
    Arm Type
    Experimental
    Intervention Type
    Biological
    Intervention Name(s)
    Induction of neural stem cells
    Intervention Description
    Brain injection iNSC
    Primary Outcome Measure Information:
    Title
    Incidence of Treatment Emergent AE
    Time Frame
    1 year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study procedures. Men and women 30-65 years old. Women must have a negative serum pregnancy test, gestation age women practice an acceptable method of contraception. At least 12 months but no more than 60 months from time of hemorrhagic stroke, with a motor neurological deficit. Documented history of single hemorrhagic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement, with correlated findings by MRI. Modified Rankin Score of 2, 3 or 4. FMMS score of 55 or less, two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 5 point change in the FMMS. Two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 4 point change in the NIHSS. Able and willing to undergo post-physical therapy/rehabilitation. Exclusion Criteria: Any disabling psychological or psychiatric disorders which may confound the study. History of more than one hemorrhagic stroke. History of another major neurological disease or injury. Cerebral soften lesion size >5cm in any one measurement. Myocardial infarction within the prior 3 months. History of seizures or current use of antiepileptic medication. History of peripheral nerve surgery, including Selective Dorsal Rhizotomy and Contralateral Seventh Cervical Nerve Transfer. Receipt of any investigational drug or device within 30 days. Receipt of any cell infusion other than blood transfusion. Any concomitant medical disease or condition noted below: Coagulopathy. Active or history of malignancy. Primary or secondary immune deficiency. Persistent MRI artifact or unable to undergo MRI. Any condition that the Investigator or primary physician feels may interfere with participation in the study or may endanger the subject. Any condition that the surgeon feels may pose complications for the surgery.

    12. IPD Sharing Statement

    Learn more about this trial

    A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke

    We'll reach out to this number within 24 hrs